Antidepressants Should Not Be Used Off-Label In Children, EMEA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
European Medicines Agency recommends that warnings highlighting the increased risk of suicidal behavior should be included in product information for SSRIs/SNRIs. If the products are used off-label in pediatric populations out of clinical necessity, children should be monitored for suicidal behavior, the agency says.
You may also be interested in...
Prozac Pediatric Indication Recommended By EU Committee
EMEA’s Committee for Medicinal Products for Human Use backed the pediatric depression indication for Lilly’s fluoxetine, but urged continued safety studies.
Prozac Pediatric Indication Recommended By EU Committee
EMEA’s Committee for Medicinal Products for Human Use backed the pediatric depression indication for Lilly’s fluoxetine, but urged continued safety studies.
Antidepressant MedGuide Distribution Imminent; Unit-Of-Use Packs To Follow
The new patient Medication Guide is expected to reach pharmacies the week of March 7. The standardized MedGuides will be issued as tear-off pads for about a year until manufacturers implement unit-of-use packaging, which would allow the guide to be pre-packaged with every prescription.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: